Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DR5VQ1
|
|||
| Drug Name |
CYT-0851
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Phase 1/2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | ||
| Company |
Cyteir Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA repair protein RAD51 homolog 1 (RAD51) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Homologous recombination | |||
| Fanconi anemia pathway | ||||
| Pathways in cancer | ||||
| Pancreatic cancer | ||||
| Pathway Interaction Database | p73 transcription factor network | |||
| ATR signaling pathway | ||||
| BARD1 signaling events | ||||
| Reactome | HDR through Single Strand Annealing (SSA) | |||
| HDR through Homologous Recombination (HRR) | ||||
| Presynaptic phase of homologous DNA pairing and strand exchange | ||||
| Meiotic recombination | ||||
| WikiPathways | DNA Damage Response | |||
| Meiotic Recombination | ||||
| ATM Signaling Pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Integrated Breast Cancer Pathway | ||||
| Homologous recombination | ||||
| Double-Strand Break Repair | ||||
| miRNA Regulation of DNA Damage Response | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03997968) A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug name CYT0851). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.